Carcinoma In Situ - ClinicalTrials.gov

A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast

RT versus full breast RT+ tumour bed lift is a time to local recurrence in women with DCIS treated with breast conserving surgery, followed by: full breast RT plus tumor bed increase, rather than the shorter one. To determine time to disease recurrence and overall survival in women with DCIS treated with breast conserving surgery and then divided breast RT plus tumour bed increase, RT using the standard fractionation schedule versus the shorter one. Breast RT+ tumour bed boost versus whole breast RT+ tumour bed enhancement; RT using the standard fractionation schedule versus the shorter version to compare the cosmetic effects. To determine the quality of life of women treated with: whole breast RT+ tumour bed boost; RT using the common fractionation scheme versus the shorter version.

Source link: https://clinicaltrials.gov/ct2/show/NCT00470236

Combination of 5-Fluorouracil and Calcipotriene in the Treatment of Superficial Basal Cell Carcinomas and Squamous Cell Carcinomas in Situ

In situ, the investigators will compare the use of two different creams for the treatment of low-risk skin cancers-superficial basal cell carcinoma and squamous cell carcinoma. 5-Fluorouracil cream is now FDA-approved for the treatment of superficial basal cell carcinoma in dermatologists around the world and in the Boston Medical Center for SCCis. Both skin cancers respond to the common treatment regimen, which is 4-weeks of the 5-fluorouracil cream. This combination cream has been shown to eliminate pre-skin cancers, actinic keratoses, and prevent future skin cancers from developing. The 2 forms of skin cancer are resistant to this shorter treatment regimen, so try this combination cream for 7-14 days to see if this shorter treatment course gives you cancer-free skin cancer. This combination cream is also used in this way to treat other subtypes of similar skin cancers.

Source link: https://clinicaltrials.gov/ct2/show/NCT05381597

A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ

Oral tamoxifen has reduced breast cancer risk by 50% in generally defined high risk women, with a 75% decrease in women at high risk due to atypical hyperplasia. The aim of the study is to determine short-term changes in background breast tissue in women with AH or LCIS who have either low-dose oral tamoxifen or topical 4-OHT gel.

Source link: https://clinicaltrials.gov/ct2/show/NCT04570956

Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features

A prospective cohort study, carried out in Canada, to determine whether the combination of clinicopathological results and the Oncotype DX DCIS score can identify a group of women at a risk of local recurrence after breast conserving surgery that do not require breast radiation therapy. We intend to screen 809 consenting women whose tumor tissue samples will be sent to Exact Sciences to determine their DCIS score. These patients will be enrolled and followed as part of the study, we expect that 526 women will have an Oncotype DX DCIS score 39 and a 10-year chance of local recurrence 10 years and a 10-year risk of local recurrence 10 percent. All patients with DCIS who require radiation oncology will be documented at each center. The DCIS score will be sent to the referring physician, according to the referring physician. The DCIS score findings will also be published on OCOG.

Source link: https://clinicaltrials.gov/ct2/show/NCT04797299

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions